NCT03323034
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Chemotherapy, Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 6 Months to 21 Years (Child, Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes:
Exclusions: Patients over 21 years of age; Patients with prior exposure to pevonedistat
https://ClinicalTrials.gov/show/NCT03323034